Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue

BACKGROUND: Hepatitis B virus (HBV) nucleos(t)ide analog (NA) therapy reduces liver disease but requires prolonged therapy to achieve hepatitis B surface antigen (HBsAg) loss. There is limited North American real-world data using non-invasive tools for fibrosis assessment and few have compared 1(st...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramji, Alnoor, Doucette, Karen, Cooper, Curtis, Minuk, Gerald Yosel, Ma, Mang, Wong, Alexander, Wong, David, Tam, Edward, Conway, Brian, Truong, David, Wong, Philip, Barrett, Lisa, Ko, Hin Hin, Haylock-Jacobs, Sarah, Patel, Nishi, Kaplan, Gilaad G, Fung, Scott, Coffin, Carla S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453764/
https://www.ncbi.nlm.nih.gov/pubmed/36159017
http://dx.doi.org/10.3748/wjg.v28.i31.4390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453764/
https://www.ncbi.nlm.nih.gov/pubmed/36159017
http://dx.doi.org/10.3748/wjg.v28.i31.4390

Ejemplares similares